The Manufacturers Life Insurance Company Acquires New Holdings in Nurix Therapeutics, Inc. $NRIX

Key Points

• The Manufacturers Life Insurance Company initiated a 168,857-share position in Nurix Therapeutics during the second quarter, valued at approximately $4.1 million. Several other institutional investors also established new stakes.
• Nurix reported weaker-than-expected quarterly results, with a loss of $0.81 per share versus the $0.73 consensus estimate and revenue of $9.04 million against expectations of $15.29 million. Analysts project a full-year loss of $2.73 per share.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $34.21, although insiders have sold 26,766 shares worth about $626,343 over the past 90 days.

The Manufacturers Life Insurance Company bought a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 168,857 shares of the company's stock, valued at approximately $4,096,000. The Manufacturers Life Insurance Company owned approximately 0.16% of Nurix Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Polymer Capital Management HK LTD acquired a new position in shares of Nurix Therapeutics during the second quarter worth $1,429,000. EP Wealth Advisors LLC acquired a new stake in shares of Nurix Therapeutics during the 2nd quarter valued at $214,000. Ieq Capital LLC acquired a new stake in shares of Nurix Therapeutics during the 2nd quarter valued at $252,000. E Fund Management Co. Ltd. bought a new stake in Nurix Therapeutics during the 2nd quarter worth $234,000. Finally, Edmond DE Rothschild Holding S.A. bought a new stake in Nurix Therapeutics during the 2nd quarter worth $2,183,000.

Nurix Therapeutics Stock Performance

Nurix Therapeutics stock opened at $26.04 on Wednesday. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of -7.55 and a beta of 1.80. Nurix Therapeutics, Inc. has a 52-week low of $8.19 and a 52-week high of $28.23. The stock's 50 day moving average price is $24.65 and its two-hundred day moving average price is $19.14.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The company had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. On average, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.73 EPS for the current year.

Insider Buying and Selling at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 4,761 shares of the company's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the transaction, the chief financial officer directly owned 40,166 shares of the company's stock, valued at $978,443.76. This represents a 10.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 1,452 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $25.47, for a total value of $36,982.44. Following the completion of the transaction, the insider owned 117,227 shares in the company, valued at approximately $2,985,771.69. This represents a 1.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 26,766 shares of company stock valued at $626,343. Insiders own 6.70% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on NRIX. Morgan Stanley increased their target price on Nurix Therapeutics from $36.00 to $38.00 and gave the company an "overweight" rating in a research report on Tuesday, July 28th. Truist Financial upped their price objective on Nurix Therapeutics from $32.00 to $34.00 and gave the company a "buy" rating in a research note on Friday, July 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nurix Therapeutics in a report on Friday, July 17th. Royal Bank Of Canada lifted their target price on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the stock an "outperform" rating in a research report on Monday, August 10th. Finally, UBS Group boosted their target price on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the stock a "buy" rating in a report on Wednesday, July 22nd. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Nurix Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $34.21.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company's pipeline includes multiple programs in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source